Memantina Aurovitas Spain (Memantine Hydrochloride)

Memantine works by blocking the NMDA‑type glutamate receptors in a non‑competitive manner. This reduces excessive calcium entry into neurons, limiting excitotoxic damage that contributes to the progressive loss of cognitive function seen in Alzheimer’s disease.

The specific dose of Memantina Aurovitas Spain is determined by the prescribing physician based on the patient’s clinical condition, renal function, and treatment response. Dosage regimens are individualized and should follow the prescriber’s instructions.

The safety of memantine in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine and galantamine are acetylcholinesterase inhibitors. Memantine is typically used in moderate to severe disease and may be combined with an acetylcholinesterase inhibitor for additive benefit.

Store the tablets at temperatures below 25 °C in their original packaging. Protect them from moisture and direct sunlight to maintain product stability throughout its shelf life.

The medication is taken orally, usually once daily with or without food, as directed by the prescribing clinician. Swallow the tablet whole with water; do not crush or chew unless specifically instructed.

Serious adverse events, although rare, include seizures, cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, and significant liver enzyme elevations. Patients should be monitored for these signs and seek immediate medical attention if they occur.

Memantina Aurovitas Spain is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled seizures, or those taking other NMDA‑receptor antagonists.